Ng Vivian G, Lansky Alexandra J
Yale University School of Medicine, New Haven, CT, USA.
Heart and Vascular Clinical Research Program, Yale University School of Medicine, PO Box 208017, New Haven, CT 06520-8017, USA.
Interv Cardiol Clin. 2016 Oct;5(4):523-532. doi: 10.1016/j.iccl.2016.06.014. Epub 2016 Jul 30.
Coronary artery disease is the leading cause of death in women. Women with ST-segment elevation myocardial infarctions continue to have worse outcomes compared with men despite advancements in therapies. Furthermore, these differences are particularly pronounced among young men and women with myocardial infarctions. Differences in the pathophysiology of coronary artery plaque development, disease presentation, and recognition likely contribute to these outcome disparities. Despite having worse outcomes compared with men, women clearly benefit from aggressive treatment and the latest therapies. This article reviews the treatment options for ST-segment elevation myocardial infarctions and the outcomes of women after treatment with reperfusion therapies.
冠状动脉疾病是女性死亡的主要原因。尽管治疗方法有所进步,但与男性相比,患有ST段抬高型心肌梗死的女性预后仍然较差。此外,这些差异在患有心肌梗死的年轻男性和女性中尤为明显。冠状动脉斑块形成的病理生理学、疾病表现和识别方面的差异可能导致了这些预后差异。尽管与男性相比预后较差,但女性显然能从积极治疗和最新疗法中获益。本文综述了ST段抬高型心肌梗死的治疗选择以及女性接受再灌注治疗后的预后情况。